LENZ Therapeutics LENZ 深 沪
等待开盘 10-01 09:30:00 美东时间
3.84
-0.020
-0.52%
华盛通- 最 高3.90
- 今 开3.90
- 成交量 78.62万股
- 最 低 3.75
- 昨 收 3.86
- 总市值 1.21亿
- 52周最高 42.98
- 市盈率 静 --
- 换手率 2.50%
- 52周最低 3.595
- 委 比 -83.85%
- 总股本 3142.03万
- 历史最高 230.79
- 量 比 0.97
- 振 幅 3.89%
- 历史最低 3.595
- 每 手 1
- 风险率 10.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gene editing stocks fall after Anthropic’s CRISPR-like discovery
Gene editing companies traded lower on Wednesday after Anthropic (ANTHRO) said that its AI model Claude has “autonomously discovered” a new enzyme system similar to the gene-editing tool CRISPR. Notab...
09-24 02:33
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $12 to $7.
08-13 00:24
LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.06) by 3.77 percent. This is a 92.45 percent decrease over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $5.486 millio...
08-12 04:12
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Buy and maintains $38 price target.
07-07 18:27
LENZ Therapeutics Announces Availability Of VIZZ Through Telehealth Platform
LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced that VIZZ is now available through a convenient telehealth p...
07-06 20:20
LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst
LENZ Therapeutics, Inc. (NASDAQ:LENZ) on Wednesday announced an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. The agreement marks LENZ’s latest effort to expand the commercial reach of its recently approved eye drop therapy beyond the U.S. market. Read Als...
06-25 01:41
LENZ Therapeutics And Arrotex Pharma Announce Exclusive License And Commercialization Agreement For Arrotex To Register And Commercialize VIZZ For Treatment Of Presbyopia In Australia And New Zealand
LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Arrotex Pharmaceuticals Pty Ltd. ("Arrotex") today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize VIZZ™ for the treatment of presbyopia in Australia and New Zealand. LENZ Therapeutics is a pharmaceuti...
06-24 20:32
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
